Search Results - latency

5 Results

Sort By:

Prevention or Treatment of Viral Infections by Inhibition of the Histone Methyltransferases EZH1/2

Herpes simplex viral infections, including herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2), are exceptionally common worldwide. These viruses establish lifelong persistent infections with cycles of lytic reactivation to produce recurrent diseases including oral and genital lesions, herpetic keratitis/blindness, congenital-developmental syndromes,...

Published: 7/25/2024 | Inventor(s): Jesse Arbuckle, Thomas Kristie

Keywords(s): DB4BXX, DB4XXX, DBXXXX, DC5BXX, DC5XXX, DCXXXX, DEXXXX, DXXXXX, EZH1/2, HERPESVIRUS, Infection, Inhibitors, Latency, Listed LPM Fenn as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Reactivation, Suppresses, VLXXXX, WKXXXX, WNXXXX, XKXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, Application > Vaccines, TherapeuticArea > Infectious Disease

Safer Attenuated Virus Vaccines with Missing or Diminished Latency of Infection

This technology describes recombinant viruses that have weakened ability to establish and/or maintain latency and their use as live vaccines. The viruses have one or more genetic mutations that allow for continued replication but that inhibit latency. The vaccine materials and methods for their construction are exemplified with the virus that causes...

Published: 7/25/2024 | Inventor(s): Lesley Pesnicak, Edward Cox, Jeffrey Cohen

Keywords(s): BUT, chickenpox, DC5BXX, DC5XXX, DCXXXX, DXXXXX, Impaired, Latency, MUTANT, Patent Category - Biotechnology, REPLICATION, UAXXXX, Vaccine, VARICELLA-ZOSTER

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, TherapeuticArea > Rare / Neglected Diseases, Application > Vaccines

Prevention and Treatment of Herpes Virus Infection by Inhibition of the JMJD2 Family of Histone Demethylases

Investigators at the NIH have discovered a potential means for preventing or treating a herpes virus infection by inhibiting the activity of the host cell’s histone demethylases. When herpesviruses enter a cell, they are inactivated by cellular defense mechanisms that wrap the viral genome in repressive chromatin structures. In order for viral replication...

Published: 7/25/2024 | Inventor(s): Yu Liang, Jodi Vogel, Jesse Arbuckle, Thomas Kristie

Keywords(s): Analogs, Chicken pox, CYTOMEGALOVIRUS, DB4XXX, DBXXXX, DEPLETION, Dimethyloxalylglycine, DMOG, DXXXXX, ENZYMES, Ester, FAMILY, HERPES, INFECTIONS, Inhibitors, JMJD, Kaposi Sarcoma, Kaposi's sarcoma; Kaposi sarcoma, Latency, Methyl, N-methoxyoxoacetyl-glycine, Patent Category - Chemistry, Prevent, Reactivation, simplex, Varicella Zoster, virus

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease

Cell Based Immunotherapy

The invention hereby offered for licensing is in the field of Immunotherapy and more specifically in therapy of autoimmune diseases such as Type I diabetes, multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosis and immune mediated allergies such as asthma as well as in transplantation-related disorders, such as graft acceptance...

Published: 7/25/2024 | Inventor(s): Ethan Shevach, Dat Tran

Keywords(s): 2, ACTIVATED, ALLOWS, Aplastic anemia, Aplastic anemia, idiopathic; Aplastic anemia, Associated, CD121b, CELL-BASED, Cells, CULTURES, EXPANSION, Expression, FOXP3+, Generate, Graft versus host disease, Human, IB3XXX, IBXXXX, Idiopathic thrombocytopenic purpura, IL-l, Immunotherapy, IXXXXX, LAP, Latency, NUMBERS, Patent Category - Biotechnology, Peptide, purification, RECEPTOR, Regulatory, SELECTIVE, Sufficient, Systemic lupus erythematosus, T, Their, Thrombocytopenic purpura, autoimmune, TYPE

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Immunology, Application > Diagnostics, Application > Research Materials

Use of Mono-Amine Oxidase Inhibitors to Prevent Herpes Virus Infections and Reactivation from Latency

Available for licensing are methods of using Monoamine Oxidase Inhibitors (MAOIs) to prevent alpha-herpesvirus lytic infections, such as those caused by Herpes simplex virus (HSV-1 or HSV-2) and Varicella zoster virus (VZV), and to possibly prevent the periodic reactivation of these viruses from latency. MAOIs have been historically used to treat depression,...

Published: 7/25/2024 | Inventor(s): Yu Liang, Thomas Kristie

Keywords(s): BBXXXX, CHEMISTRY, DB4BXX, DB4XXX, DBXXXX, DXXXXX, HERPES, HSV, HSV-1, hsv-2, Infection, INFECTIONS, Inhibitors, Latency, Mono-Amine, Mono-Anine, OXIDASE, Prevent, Reactivation, Reactiviation, Simpex, simplex, Variacella-zoster, Varicella Zoster, virus, VZV, ZOSTER

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease